Is InChronicles down?

NO

Current InChronicles status

Status Up
Up

InChronicles Status Details

Full cycle product for R&D teams in Pharmaceutical Industry. The product includes eTMF, CTMS, Logistics and eDMS with eSignature support.
This is an unofficial InChronicles status page
InChronicles's website is at inchronicles.com
Check out our list of InChronicles alternatives

Community feedback on InChronicles's status

Log in or Post with

InChronicles Alternatives

  1. Visit website

    The PAQATO After-Sales Experience Platform is the growth driver that makes online stores successful for tomorrow.

    Visit website paid €349.0 / Monthly

  2. /bsi-ctms-alternatives

    BSI CTMS covers all aspects of clinical trial management. It is the most intuitive and flexible system on the market. Test us out.

  3. /medidata-ctms-alternatives

    Medidata CTMS seamlessly integrates with Medidata Rave to provide real-time views into study progress without manual tracking.

  4. /realtime-ctms-alternatives

    RealTime-CTMS is a clinical trial management system designed to streamline operations within a clinical research site.

  5. /protocol-manager-ctms-alternatives

    Protocol Manager (CTMS) is a clinical trial management system that helps users to manage clinical operations and trials of drugs and vaccines in all the phases.

  6. /openclinica-alternatives

    OpenClinica is an open source clinical trials software.

  7. /clinion-ctms-alternatives

    Integrated Solution To Plan, Manage and Track All Your Studies

  8. /simpletrials-alternatives

    Web-based clinical trial management system


» All InChronicles alternatives

SaaSHub's Down Detector checks the status of services automatically and regularly. However, we cannot promise 100% accuracy. That is why we depend on user reported issues as well. The InChronicles status here can help you determine if there is a global outage and InChronicles is down for everyone or if it is just you who is experiencing problems. Please report any issues to help others know the current status.